Welcome to the e-CCO Library!

P546 Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Narula1, E. Wong1, A. Achuthan1, P. Dulai2, J.F. Colombel3, J.K. Marshall1, M. Ferrante4, W. Reinisch5

Created: Thursday, 30 January 2020, 10:12 AM
P546: Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Reinisch, W.(1)*;Panaccione, R.(2);Duijvestein, M.(3);Ceballos Santos, D.(4);Melmed, G.Y.(5);Xuan, S.(6);Wegrzyn, L.(6);Levy, G.(6);Ilo, D.(6);Sanchez Gonzalez, Y.(6);
Created: Friday, 14 July 2023, 11:05 AM
P546: Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.
Year: 2022
Source: ECCO'22
Authors: Ranjan, M.K.(1);Kante, B.(1);Vuyyuru, S.K.(1);Kumar, P.(1);Mundhra, S.K.(1);Golla, R.(1);Sharma, R.(2);Das, P.(3);Sahni, P.(4);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P546: The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype
Year: 2021
Source: ECCO'21 Virtual
Authors: Resál, T.(1);Farkas, K.(1);Molnár, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P546: Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Torres1, D. Martín Arranz2, M. Sánchez Azofra2, E. Martín Arranz2, L. Garcia2, P. Nozal3, J. Pascual1, I. Apraiz1, M. López1, D. Arteta1, D. Nagore*1

Created: Friday, 22 February 2019, 9:41 AM
P546: Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Bressler1*, A.-J. Greenup1, M. Bassel2, D. Stein3, M. Soni3, G. Radulescu4, C. Neish4, J.M. Khalid5, D. Demuth5

Created: Thursday, 21 February 2019, 9:14 AM
P546: Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Serra K.*1, Rodríguez-Alonso L.1, Padullés N.2, Rodríguez-Moranta F.1, Arajol C.1, Gilabert P.1, Rodríguez R.1, Bas J.3, Morandeira-Rego F.3, Santacana E.2, Padullés A.2, Guardiola J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P547 Inadequate vitamin C status and association with inflammatory biomarkers in adults with active Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Wall1, K. MacFarlane2, A. Carr3, A. Day4, R. Gearry1

Created: Thursday, 30 January 2020, 10:12 AM
P547: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Eriksson1, S. Rundquist1*, V. Lykiardopoulos2, P. Karlén3, O. Grip4, C. Söderman5, S. Almer6, E. Hertervig7, J. Gunnarsson8, C. Malmgren9, J. Delin10, H. Strid11, M. Sjöberg12, D. Öberg13, D. Bergemalm1, R. Udumyan14, H. Hjortswang2, The SWIBREG SVEAH Study Group, J. Halfvarson1

Created: Thursday, 21 February 2019, 9:14 AM
P547: Distribution of mesenteric macrophage polarisation: a guide for surgical resections in Crohn’s disease?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. van der Meer*1, K. Wasmann2, J. van der Bilt3, M. Becker1, W. Bemelman2, M. Wildenberg1,4, C. Buskens2

Created: Friday, 22 February 2019, 9:41 AM
P547: Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
Year: 2022
Source: ECCO'22
Authors: Schreiber , S.(1);Galinsky , K.(2);Aubrecht , J.(2);Juarez , J.(2);Agboton , C.(3);Loftus Jr , E.V.(4);Danese , S.(5);
Created: Friday, 11 February 2022, 3:56 PM
P547: Is there an association between bariatric surgery and Crohn's disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Brcic I.*1, Todoroff A.2, Baumgartner K.2, Langner C.1, Gröchenig H.P.3

Created: Wednesday, 20 February 2019, 10:36 AM
P547: Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Barnes, E.(1)*;Zhang, X.(2);Long, M.(3);Herfarth, H.(1);Kappelman, M.(4);
Created: Friday, 14 July 2023, 11:05 AM
P547: Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: KhorshidFASGE, M.(1);Alboraie, M.(2);Abbas, W.(3);Sayed, Z.E.(3);El-Nady, M.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Fischer1, S. Mesfin1, E. Klenske1, H. Schmitt1, F. Vitali1, S. Hirschmann1, A. Ramming2, S. Zundler1, T. Rath1, S. Krebs3, F. Dörje3, W. Uter4, D. Nagore5, S. Meyer4, M.F. Neurath1, R. Atreya1

Created: Thursday, 30 January 2020, 10:12 AM
P548: Drug Survival in Patients with Inflammatory Bowel disease: An observational study
Year: 2021
Source: ECCO'21 Virtual
Authors: Kubesch, A.(1);Grimm, L.(1);Stratmann, K.(1);Knabe, M.(1);Filmann, N.(2);Sprinzl, K.(1);Hausmann, J.(1);Blumenstein, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P548: Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Atreya, R.(1)*;Irving, P.(2);Fujiya, M.(3);Colombel, J.F.(4);Danese, S.(5);Peyrin-Biroulet, L.(6);Bessissow, T.(7);Panaccione, R.(8);D'Haens, G.(9);van Haaren, S.(10);Neimark, E.(11);Zambrano, J.(12);Zhang, Y.(13);Kligys, K.(10);Ferrante, M.(14);
Created: Friday, 14 July 2023, 11:05 AM
P548: External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Van Erp, L.W.(1);Thomas, P.W.A.(2);Groenen, M.J.M.(1);Bloem, S.(3);Russel, M.G.V.M.(4);Römkens, T.E.H.(5);Wahab, P.J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P548: Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lee J.M.*1, Lee K.-M.1, Kim H.-S.2, Ye B.D.3, Park S.J.4, Park S.H.3, Im J.P.5, Jang B.I.6, Kim D.B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Ferrante*, B. Verstockt, L. Gijbels, G. Van Assche, S. Vermeire

Created: Thursday, 21 February 2019, 9:14 AM